VERA - NASDAQ
Vera Therapeutics, Inc.
$31.27
-7.9%Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
At a Glance
Live SnapshotNo Revenue Data
VERA has not reported any revenue values in the available annual periods.
Vera Therapeutics, Inc. Profit Bridge
Profitability Analysis
Vera Therapeutics, Inc. Income Statement
VERA • NASDAQ
| Vera Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
GROSS PROFIT | |||||||
(468K) | (0.0) | (0.0) | -846K | (0.0) | (251K) | (509K) | |
-468K | 0.0 | 0.0 | 846K | 0.0 | -251K | -509K | |
OPERATING INCOME | |||||||
(315.5M) | (167.2M) | (102M) | (91.7M) | (34.4M) | (47.8M) | (11.7M) | |
(100.2M) | (41M) | (23.8M) | (21.9M) | (11.9M) | (3.9M) | (4.4M) | |
(215.3M) | (126.2M) | (78.2M) | (69.8M) | (22.5M) | (43.9M) | (7.3M) | |
-315.5M | -167.2M | -102M | -90.9M | -34.4M | -48.1M | -12M | |
PRE-TAX INCOME | |||||||
(7.5M) | (7.6M) | (3.8M) | (992K) | (20K) | (166K) | (51K) | |
16.9M | 13.1M | 4.2M | 758K | -5K | -158K | 108K | |
15.9M | 15M | 6M | 1.8M | 1.8M | -5.4M | 108K | |
-299.6M | -152.1M | -96M | -89.1M | -32.6M | -53.4M | -11.9M | |
NET INCOME | |||||||
-1K | (1K) | (1K) | (1K) | (1K) | (1K) | (1K) | |
-299.6M | -152.1M | -96M | -89.1M | -32.6M | -53.4M | -11.9M |
SEC Filings
VERA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 09, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 16, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 10, 2025 | December 09, 2025 | 2025 |
Related Guides
Continue your VERA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.